Why Prime Medicine Stock Soared Nearly 12% Higher on Monday

Changes are afoot at the company, and investors welcomed them. Next-generation healthcare company Prime Medicine (PRME 11.85%) was exactly what the doctor ordered for ailing portfolios on the first trading day of the week. On a company update and news of collaboration with a top healthcare business, investors piled into the gene-editing specialist and sent its share price almost 12% higher today. That compared very favorably with the 0.4% gain in the bellwether S&P 500 index. A new development deal Arguably ...